References
1. World Health Organization Classification of Tumours of Haematopoietic
and Lymphoid Tissues. 4th ed. Swerdlow SH, Campo E, Harris NL, et al
Eds. IARC Press, Lyon, 2017.
2. Seymour JF, Kipps TJ, Eichhorst B et al. Venetoclax-rituximab in
relapsed or refractory chronic lymphocytic leukemia. N Engl J Med
378:1107-1120, 2018.3.
3. Cheson BD, Heitner Enschede S, Cerri E et al. Tumor lysis syndrome in
chronic lymphocytic leukemia with novel targeted agents. Oncologist
22:1283-1291, 2017.
4. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and
classification of chronic kidney disease: a position statement from
Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int
67:2089-2100, 2005.
5. Swan D, Delaney C, Natoni A, O’Dwyer M, Krawczyk J. Successful
venetoclax salvage in the setting of refractory, dialysis-dependent
multiple myeloma with t(11;14). Hematologica 105:e141-e143, 2020.
6. Salem AH, Agarwal SK, Dunbar M, Enschede SLH, Humerickhouse RA, Wong
SL. Pharmacokinetics of Venetoclax, a novel BCL-2 inhibitor, in patients
with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin
lymphoma. J Clin Pharmacol 57:484-492, 2017.
7. Salem AH, Dave N, Marbury T et al. Pharmacokinetics of the BCL-2
inhibitor Venetoclax in subjects with hepatic impairment. Clin
Pharmacokinet 58:1091-1100, 2019.